Spruce Biosciences Q1 net loss $12.8M; CAH trials near enrollment goals; PCOS study topline Q3 2023

SPRUCE BIOSCIENCES, INC.

2023-Q1 EPS reported -$0.40 revenue$1,964,000

Cash and investments $118.6M as of March 31, 2023; with Kaken $15M upfront, runway into H1 2025.
Collaboration revenue $2.0M (Kaken deal); R&D $11.7M; net loss $12.8M vs $11.8M YoY.
CAHmelia-204 (adult CAH) 50% enrolled; CAHmelia-203 approaching 75% enrollment.
P.O.W.E.R. PCOS Phase 2 fully enrolled (27 subjects); topline results expected Q3 2023.
Appointed Mo Noursalehi, Ph.D., as SVP of Biometrics; completed $53.6M private placement.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

SPRUCE BIOSCIENCES, INC. reported financial results for the quarter ended March 31, 2023.

Period: the quarter ended March 31, 2023
Result: reported results

Exact text from the filing

On May 15, 2023, Spruce Biosciences, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended March 31, 2023 and providing corporate updates.

View on SEC.gov

10 earnings releases filed in the last 30 days. Browse all earnings releases →

SPRUCE BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0000950170-23-021979

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.